Actinium Pharmaceuticals, Inc. (ATNM)
NYSEAMERICAN: ATNM · Real-Time Price · USD
1.200
0.00 (0.00%)
Mar 9, 2026, 3:22 PM EDT - Market open
Actinium Pharmaceuticals Employees
Actinium Pharmaceuticals had 37 employees as of December 31, 2024. The number of employees decreased by 12 or -24.49% compared to the previous year.
Employees
37
Change (1Y)
-12
Growth (1Y)
-24.49%
Revenue / Employee
$3,600
Profits / Employee
-$1,383,960
Market Cap
37.44M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Xilio Therapeutics | 64 |
| Atara Biotherapeutics | 38 |
| Jasper Therapeutics | 27 |
| Lisata Therapeutics | 26 |
| PDS Biotechnology | 24 |
| INmune Bio | 22 |
| Sensei Biotherapeutics | 15 |
| CervoMed | 15 |
ATNM News
- 20 days ago - BIOEMTECH and NorthStar Medical Radioisotopes Announce Strategic Supply Agreement for Actinium-225 to Support Preclinical Radiopharmaceutical Research - Business Wire
- 3 months ago - Actinium Pharmaceuticals Presents New Preclinical Data Demonstrating Potent Anti-Tumor Activity of ATNM-400 Across Multiple Breast Cancer Subtypes Including Hormone Receptor-Positive, Triple-Negative, and Tamoxifen- and HER2 Therapy-Resistant Breast Cancer Models at SABCS 2025 - PRNewsWire
- 3 months ago - Actinium Pharmaceuticals Announces ATNM-400 Data Demonstrating Potent Efficacy in Triple-Negative Breast Cancer and Ability to Overcome Endocrine and HER2-Targeted Therapy Resistance Being Presented at the San Antonio Breast Cancer Symposium - PRNewsWire
- 4 months ago - The Race for the Global Radiotherapy Cancer Market; Actinium Pharmaceuticals' (ATNM) Big Bet - Newsfile Corp
- 4 months ago - Actinium Announces Superior Anti-Tumor Activity of ATNM-400 in Lung Cancer Compared to the Leading First, Second and Third-Line Approved EGFR Mutant Therapies and Mechanistic Synergy with Osimertinib at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics - PRNewsWire
- 4 months ago - Actinium Pharmaceuticals Presents New Data Demonstrating Potent and Durable Efficacy of ATNM-400, a First-in-Class Multi-Tumor Actinium-225 Radiotherapy, at the 32nd Annual Prostate Cancer Foundation Scientific Retreat - PRNewsWire
- 5 months ago - Actinium Pharmaceuticals to Unveil the Multi-Tumor Potential of ATNM-400, a First-in-Class Actinium-225 Radiotherapy, with Data in Non-Small Cell Lung Cancer at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics - PRNewsWire
- 5 months ago - Actinium to Present ATNM-400 Preclinical Data Highlighting Durable Tumor Control and Ability to Overcome Resistance to Standard-of-Care Prostate Cancer Therapies at the 32nd Annual Prostate Cancer Foundation Scientific Retreat - PRNewsWire